Ambalal Sarabhai Enterprises Stock Falls to 52-Week Low of Rs.29.1

Recent Price Movement and Market Context

On 21 Nov 2025, Ambalal Sarabhai Enterprises recorded a day change of -1.34%, underperforming its Pharmaceuticals & Biotechnology sector by 1.1%. The stock has declined over the past two consecutive sessions, accumulating a total return of -3.56% during this period. The current price of Rs.29.1 stands well below its 52-week high of Rs.68, reflecting a substantial shift in market valuation over the last year.

In contrast, the broader market index, Sensex, opened lower at 85,347.40 points, down 285.28 points or 0.33%, and was trading at 85,393.92 points (-0.28%) at the time of reporting. Notably, the Sensex remains close to its 52-week high of 85,801.70, just 0.48% away, and is trading above its 50-day moving average, which itself is positioned above the 200-day moving average, indicating a generally bullish trend in the wider market.

Technical Indicators and Moving Averages

Ambalal Sarabhai Enterprises is currently trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. This persistent position beneath all major moving averages suggests sustained downward momentum in the stock price. Such a technical profile often signals caution among market participants, as the stock has not shown signs of recovery relative to its recent trading history.

Financial Performance Overview

Over the past year, Ambalal Sarabhai Enterprises has recorded a return of -47.37%, contrasting with the Sensex’s positive return of 10.67% during the same period. The stock has also underperformed the BSE500 index across multiple time frames, including the last three years, one year, and three months, indicating a prolonged period of relative weakness.

Long-term growth metrics reveal that net sales have expanded at an annual rate of 7.00% over the last five years. However, the company’s return on capital employed (ROCE) averages 4.55%, which is considered modest within the Pharmaceuticals & Biotechnology sector. This level of capital efficiency may contribute to the subdued market valuation.

Quarterly and Cash Flow Analysis

Recent quarterly results show a profit before tax (PBT) of Rs.-1.66 crore, representing a decline of 548.6% compared to the previous four-quarter average. The net profit after tax (PAT) for the quarter stood at Rs.-0.56 crore, down 111.3% relative to the same benchmark. Operating cash flow for the year is reported at Rs.-17.62 crore, marking the lowest level recorded in recent periods. These figures highlight challenges in near-term profitability and cash generation.

Valuation and Peer Comparison

Despite the recent price decline, Ambalal Sarabhai Enterprises exhibits an enterprise value to capital employed ratio of 1.5, which may be viewed as attractive relative to its sector peers. The stock is trading at a discount compared to the average historical valuations of comparable companies within the Pharmaceuticals & Biotechnology industry. Over the past year, while the stock price has declined by 46.83%, the company’s profits have risen by 24.8%, resulting in a price/earnings to growth (PEG) ratio of 0.6.

Shareholding Pattern

The majority of Ambalal Sarabhai Enterprises’ shares are held by non-institutional investors, which may influence trading dynamics and liquidity considerations in the stock.

Summary of Key Metrics

To summarise, Ambalal Sarabhai Enterprises is currently trading at Rs.29.1, its lowest level in the past 52 weeks. The stock’s performance over the last year has been notably weaker than the broader market, with a return of -47.37% compared to the Sensex’s 10.67%. The company’s financial indicators show subdued profitability and cash flow, with recent quarterly results reflecting losses and a negative operating cash flow for the year.

Technically, the stock remains below all major moving averages, signalling continued downward pressure. Valuation metrics suggest the stock is trading at a discount relative to peers, supported by a modest enterprise value to capital employed ratio and a PEG ratio below 1. However, these factors have not translated into price stability or recovery in recent months.

Meanwhile, the broader market environment remains relatively positive, with the Sensex trading near its 52-week high and maintaining bullish moving average alignments. This divergence highlights the specific challenges faced by Ambalal Sarabhai Enterprises within its sector and the wider market context.

Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →